Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial.Citation formats

  • Authors:
  • William W Busse
  • Eugene R Bleecker
  • Eric D Bateman
  • Jan Lötvall
  • Richard Forth
  • And 4 others
  • External authors:
  • Angela M Davis
  • Loretta Jacques
  • Brett Haumann
  • Ashley Woodcock

Standard

Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial. / Busse, William W; Bleecker, Eugene R; Bateman, Eric D; Lötvall, Jan; Forth, Richard; Davis, Angela M; Jacques, Loretta; Haumann, Brett; Woodcock, Ashley.

In: Thorax, Vol. 67, No. 1, 01.2012, p. 35-41.

Research output: Contribution to journalArticle

Harvard

Busse, WW, Bleecker, ER, Bateman, ED, Lötvall, J, Forth, R, Davis, AM, Jacques, L, Haumann, B & Woodcock, A 2012, 'Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial.', Thorax, vol. 67, no. 1, pp. 35-41. https://doi.org/10.1136/thoraxjnl-2011-200308

APA

Vancouver

Author

Busse, William W ; Bleecker, Eugene R ; Bateman, Eric D ; Lötvall, Jan ; Forth, Richard ; Davis, Angela M ; Jacques, Loretta ; Haumann, Brett ; Woodcock, Ashley. / Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial. In: Thorax. 2012 ; Vol. 67, No. 1. pp. 35-41.

Bibtex

@article{1f60f561eda64355b7b8b62295a05e4b,
title = "Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial.",
abstract = "BACKGROUND: Fluticasone furoate (FF) is a novel inhaled corticosteroid with 24 h activity. FF is being developed as a once-daily treatment in combination with the long-acting β(2) agonist vilanterol trifenatate for asthma and chronic obstructive pulmonary disease. OBJECTIVES: To determine the optimal dose(s) of FF for treating patients with asthma. METHODS: An 8-week multicentre, randomised, double-blind study. 627 patients with persistent moderate-to-severe asthma, symptomatic on medium-dose inhaled corticosteroid therapy, were randomised to placebo, FF 200, 400, 600 or 800 μg (once daily in the evening using a novel dry powder inhaler), or fluticasone propionate 500 μg twice daily (via Diskus™/Accuhaler™). The primary efficacy measure was mean change from baseline in pre-dose evening forced expiratory volume in one second (FEV(1)). Other endpoints included morning and evening peak expiratory flow, and rescue/symptom-free 24 h periods. RESULTS: Each dose was significantly superior to placebo for the primary endpoint (p",
author = "Busse, {William W} and Bleecker, {Eugene R} and Bateman, {Eric D} and Jan L{\"o}tvall and Richard Forth and Davis, {Angela M} and Loretta Jacques and Brett Haumann and Ashley Woodcock",
year = "2012",
month = "1",
doi = "10.1136/thoraxjnl-2011-200308",
language = "English",
volume = "67",
pages = "35--41",
journal = "Thorax",
issn = "0040-6376",
publisher = "BMJ",
number = "1",

}

RIS

TY - JOUR

T1 - Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial.

AU - Busse, William W

AU - Bleecker, Eugene R

AU - Bateman, Eric D

AU - Lötvall, Jan

AU - Forth, Richard

AU - Davis, Angela M

AU - Jacques, Loretta

AU - Haumann, Brett

AU - Woodcock, Ashley

PY - 2012/1

Y1 - 2012/1

N2 - BACKGROUND: Fluticasone furoate (FF) is a novel inhaled corticosteroid with 24 h activity. FF is being developed as a once-daily treatment in combination with the long-acting β(2) agonist vilanterol trifenatate for asthma and chronic obstructive pulmonary disease. OBJECTIVES: To determine the optimal dose(s) of FF for treating patients with asthma. METHODS: An 8-week multicentre, randomised, double-blind study. 627 patients with persistent moderate-to-severe asthma, symptomatic on medium-dose inhaled corticosteroid therapy, were randomised to placebo, FF 200, 400, 600 or 800 μg (once daily in the evening using a novel dry powder inhaler), or fluticasone propionate 500 μg twice daily (via Diskus™/Accuhaler™). The primary efficacy measure was mean change from baseline in pre-dose evening forced expiratory volume in one second (FEV(1)). Other endpoints included morning and evening peak expiratory flow, and rescue/symptom-free 24 h periods. RESULTS: Each dose was significantly superior to placebo for the primary endpoint (p

AB - BACKGROUND: Fluticasone furoate (FF) is a novel inhaled corticosteroid with 24 h activity. FF is being developed as a once-daily treatment in combination with the long-acting β(2) agonist vilanterol trifenatate for asthma and chronic obstructive pulmonary disease. OBJECTIVES: To determine the optimal dose(s) of FF for treating patients with asthma. METHODS: An 8-week multicentre, randomised, double-blind study. 627 patients with persistent moderate-to-severe asthma, symptomatic on medium-dose inhaled corticosteroid therapy, were randomised to placebo, FF 200, 400, 600 or 800 μg (once daily in the evening using a novel dry powder inhaler), or fluticasone propionate 500 μg twice daily (via Diskus™/Accuhaler™). The primary efficacy measure was mean change from baseline in pre-dose evening forced expiratory volume in one second (FEV(1)). Other endpoints included morning and evening peak expiratory flow, and rescue/symptom-free 24 h periods. RESULTS: Each dose was significantly superior to placebo for the primary endpoint (p

U2 - 10.1136/thoraxjnl-2011-200308

DO - 10.1136/thoraxjnl-2011-200308

M3 - Article

VL - 67

SP - 35

EP - 41

JO - Thorax

JF - Thorax

SN - 0040-6376

IS - 1

ER -